(Q36304822)

13 August 2017

1 reference

title

Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia (English)

1 reference

13 August 2017

1 reference

2

Caroline M Perry

1 reference

13 August 2017

Caroline Fenton

1

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

65

1 reference

13 August 2017

issue

16

1 reference

13 August 2017

page(s)

2405-2427

1 reference

Mylotarg: antibody-targeted chemotherapy comes of age.

13 August 2017

cites work

1 reference

12 December 2020

Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematolog

1 reference

12 December 2020

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin

1 reference

12 December 2020

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

1 reference

12 December 2020

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

1 reference

12 December 2020

Current use and future development of gemtuzumab ozogamicin

1 reference

12 December 2020

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

12 December 2020

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

1 reference

12 December 2020

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

1 reference

12 December 2020

Acute myeloid leukaemia: optimising treatment in elderly patients

1 reference

12 December 2020

Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup

1 reference

12 December 2020

Unanswered questions in acute myeloid leukaemia

1 reference

12 December 2020

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

12 December 2020

Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission

1 reference

12 December 2020

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients

1 reference

12 December 2020

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

1 reference

12 December 2020

Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.

1 reference

12 December 2020

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

12 December 2020

The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin

1 reference

12 December 2020

Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly

1 reference

12 December 2020

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

1 reference

12 December 2020

Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia

1 reference

12 December 2020

Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.

1 reference

12 December 2020

ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients

1 reference

12 December 2020

1 reference

12 December 2020

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

1 reference

12 December 2020

New targets for therapy in acute myeloid leukemia.

1 reference

12 December 2020

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

12 December 2020

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

12 December 2020

The difficult problem of acute myeloid leukemia in the older adult

1 reference

12 December 2020

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

12 December 2020

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

12 December 2020

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

1 reference

12 December 2020

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

1 reference

12 December 2020

Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

1 reference

12 December 2020

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

1 reference

12 December 2020

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

1 reference

12 December 2020

The challenge of acute myeloid leukemia in older patients

1 reference

12 December 2020

A systematic overview of chemotherapy effects in acute myeloid leukaemia

1 reference

12 December 2020

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

1 reference

12 December 2020

Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia

1 reference

12 December 2020

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

12 December 2020

Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia

1 reference

12 December 2020

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

12 December 2020

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

12 December 2020

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

1 reference

12 December 2020

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

12 December 2020

Drug therapy for acute myeloid leukemia

1 reference

12 December 2020

Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr.

1 reference

12 December 2020

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

1 reference

12 December 2020

Gemtuzumab ozogamicin

1 reference

12 December 2020

Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

1 reference

12 December 2020

10.2165/00003495-200565160-00014

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1008289937

0 references

1 reference